Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn

Core Viewpoint - Moderna Inc. reported third-quarter revenue of $1.83 billion, exceeding the consensus estimate of $1.25 billion, driven by increased sales in the U.S. market following the launch of the updated COVID-19 vaccine [1] Group 1: Financial Performance - The revenue growth was attributed to higher sales in the U.S. market due to the earlier launch of the updated COVID-19 vaccine [1] - Analysts have adjusted price targets for Moderna, with one reducing it from $110 to $90 based on updated commercial risk expectations and lower sales forecasts for COVID-19 and RSV vaccines [3] - Another analyst lowered the price target from $46 to $38, citing challenges from declining COVID demand and market share loss to Pfizer [4] Group 2: Market Sentiment and Stock Performance - Moderna's stock initially rose but ended lower, likely due to slowing vaccine trends and uncertainty regarding the company's respiratory vaccine lineup [2] - The stock was reported down 6.33% at $47.10 as of the last check [6] Group 3: Future Outlook - Oppenheimer remains optimistic about the long-term potential of Moderna's RSV vaccine, mRESVIA, and believes the company is well-positioned for future growth [5] - The company expects cost of sales to be 40-45% of product sales for the year, with R&D expenses anticipated to be between $4.6 billion and $4.7 billion [6]